Scinai Immunotherapeutics (SCNI) Return on Capital Employed (2018 - 2024)

Scinai Immunotherapeutics has disclosed Return on Capital Employed across 6 years of filings, most recently posting 78.18% for Q4 2024.

• Return on Capital Employed for Q4 2024 came in at 78.18%, down 8961.0% year-over-year; the trailing twelve-month figure through Dec 2024 was 78.18% (down 8961.0% YoY), and the FY2025 annual result was 0.1%, up 6316.0% from the prior year.
• Return on Capital Employed came in at 78.18% for Q4 2024 at Scinai Immunotherapeutics, down from 67.4% in the prior quarter.
• In the past five years, Return on Capital Employed ranged from a high of 81.29% in Q3 2020 to a low of 1968.49% in Q4 2020.
• The 5-year median for Return on Capital Employed is 55.19% (2024), against an average of 175.91%.
• Across the five-year window, Return on Capital Employed soared 194502 bps in 2021 and plunged 16148 bps in 2023, its largest moves.
• Scinai Immunotherapeutics' Return on Capital Employed stood at 1968.49% in 2020, then surged by 99 bps to 23.47% in 2021, then sank by 219 bps to 74.94% in 2022, then jumped by 115 bps to 11.42% in 2023, then plunged by 784 bps to 78.18% in 2024.
• The last three Return on Capital Employed figures came in at 78.18% (Q4 2024), 67.4% (Q3 2024), and 55.19% (Q2 2024), per Business Quant data.